USING FUSEON IN PATIENTS WITH HIV INFECTION AND TUBERCULOSIS
https://doi.org/10.22328/2077-9828-2014-6-4-77-81
Abstract
In one of two groups of HIV patients having tuberculosis, Enfuvitrid (Fuseon) was included in HAART regimen for 6 months. The use of Fuseon was associated with a more rapid and pronounced increase in CD4 cell counts and decrease in HIV load. The incidence of the was not increased in Fuseon-treated group. The results of TB treatment in patients who received HAART including Fuseon were more favorable, first of all, in that mortality rate decreased. The long-term results of follow-up show a decrease in the incidence of TB relapse in patients treated with Fuseon.
Keywords
About the Author
A. M. Panteleev
First Pavlov State Medical University of Saint-Petersburg; City TB Hospital № 2
Russian Federation
Russian Federation
References
1. Покровский В.В., Юрин О.Г., Кравченко А.В. Протоколы диспансерного наблюдения и лечения больных ВИЧ-инфекцией // Эпидемиология и инфекционные болезни. Актуальные вопросы.- 2012.- № S6.- С. 1-28.
2. Кравченко А.В., Голохвастова Е.Л., Виноградова Е.Н., Волова Л.Ю. Высокоактивная антиретровирусная терапия у больных ВИЧ-инфекцией с множественной резистентностью ВИЧ к антиретровирусным препаратам // Эпидемиология и инфекционные болезни.- 2008.- № 3.- С. 51-54.
3. Madruga J.V., Cahn P., Grinsztejn B., Haubrich R., Lalezari J., Mills A., Pialoux G., Wilkin T., Peeters M., Vingerhoets J., de Smedt G., Leopold L., Trefiglio R., Woodfall B. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomized, double-blind, placebo-controlled trial // Lancet.- 2007.- Vol. 370 (9581).- P. 29-38.
4. Soria A., Cavarelli M., Sala S., Alessandrini A. I., Scarlatti G., Lazzarin A., Castagna A. Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations // J. Med. Virol.- 2008.- Vol. 80 (6).- P 937-941.
5. Bonora S., Calcagno A., Cometto C. Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study // Infection.- 2012.- Vol.40 (1).- P 69-75.
6. Clotet B., Capetti A., Soto-Ramirez L.E. A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study // J. Antimicrob. Chemother.- 2008.- Vol. 62 (6).- P 1374-1378.
7. Reynes J., Arasth K., Clotet B., Cohen C., Cooper D.A., Delfraissy J.F., Eron J.J., Henry K., Katlama C. Kuritzkes TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals // AIDS Patient Care STDS.- 2007.- Vol. 21 (8).- P 533-543.
8. Nelson M., Araste’h K., Clotet B. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials // J. Acquir. Immune Defic. Syndr.- 2005.- Vol. 40 (4).- P 404-412.
9. Кравченко А.В., Кузнецова А.В., Козырев О.А. Ингибитор слияния энфувиртид в схемах АРВТ у больных с ВИЧ-инфекцией и туберкулезом // ВИЧ-инфекция и иммуносупрессии.- 2010.- Т. 2, № 4.- С. 35-41.
Review
For citations:
Panteleev A.M. USING FUSEON IN PATIENTS WITH HIV INFECTION AND TUBERCULOSIS. HIV Infection and Immunosuppressive Disorders. 2014;6(4):77-81. (In Russ.) https://doi.org/10.22328/2077-9828-2014-6-4-77-81
Views:
537
.png)
Email this article 